Flexion nabs FDA OK for its potential blockbuster osteoarthritis drug, triggering new buyout buzz
The buyout buzz around Flexion $FLXN is spiking this weekend, after the FDA came through with an approval of its injectable drug for osteoarthritis-related knee …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
